Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,
Novo Nordisk’s obesity drug isn’t even available in the UK yet, but the government has already launched a pilot programme that could see access to the drug expanded throug
Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W
Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge
Novo Nordisk has said it will temporarily reduce production of the lower starting doses of its weight-loss drug Wegovy, as demand for the therapy continues to challenge it
Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.